Carcinoembryonic antigen in the evaluation of therapy of primary and metastatic colorectal cancer

Australian and New Zealand Journal of Surgery

Volumn 66, Issue 8, 1996, Pages 515-519

  Adams, Warwick J ^a   Morris, David L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

carcinoembryonic antigen; colorectal cancer

Indexed keywords

CARCINOEMBRYONIC ANTIGEN;

ADVANCED CANCER; ANTIGEN DETECTION; COLORECTAL CANCER; DISEASE COURSE; FOLLOW UP; HUMAN; PATIENT MONITORING; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

EID: 0029745001     PISSN: 00048682     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-2197.1996.tb00800.x     Document Type: Review

References (70)

1. Fucini C, Tommasi S, Rosi S et al. Follow up of colorectal carcinoma resected for cure. An experience with CEA, TPA, CA 19.9 analysis and second look surgery. Dis. Colon Rectum 1987; 30: 273-7.
2. Filella X, Molina R, Pique J et al. Use of CA 19.9 in the early detection of recurrences in colorectal cancer: Comparison with CEA, Tumor Biol. 1994; 15: 1-6.
3. Eskelinen M, Pasenen P, Kulju A et al. Clinical evaluation of serum tumour markers CEA, CA 50 and CA 242 in colorectal cancer. Anticancer Res. 1994; 14: 1427-32.
4. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 1993; 270: 943-7.
5. Gold P, Freedman S. Demonstration of tumor-specific antigens in human colonic carcinoma by immunological tolerance and absorption techniques. J. Exp. Med. 1965; 121: 439-62.
6. Matsuoka Y. Chemical and antigenic structure of CEA analysed by using recombinant CEA peptides and monoclonal antibodies. In: Ting ST, Chen J-S, Schwartz MK (eds). Human tumor markers: Proceedings of the international symposium on human tumor markers. Amsterdam: Excerpta Medica, 1989; 185-98.
7. Cutait R, Alves V, Lopez L et al. Restaging of colorectal cancer based on CEA and cytokeratins. Dis. Colon. Rectum 1991; 34: 917-20.
8. Zeng Z, Cohen AM, Urmacher C. Usefulness of carcinoembryonic antigen monitoring despite normal preoperative values in node-positive colon cancer patients. Dis. Colon Rectum 1993; 36: 1063-8.
9. Wiggers T, Arends J, Verstijnen C, Moerkerk P, Bosman F. Prognostic significance of CEA immunoreactivity patterns in large bowel carcinoma tissue. Br. J. Cancer 1986; 54: 409-14.
10. Shi Z, Tsao D, Kim Y. Subcellular distribution, synthesis and release of carcinoembryonic antigen in cultured human colon adenocarcinoma cell lines. Cancer Res. 1983; 43: 4045-9.
11. O'Brien M, Zamcheck N, Burke B, Kirkham S, Saravis C, Gottlieb L. Immunocytochemical localisation of carcinoembryonic antigen in benign and malignant colorectal tissues: Assessment of diagnostic value. Am. J. Clin. Pathol. 1981; 75: 283-91.
12. Nakane P, Watanabe T. Distribution of oncodevelopmental markers in neoplastic cells: Therapeutic implications. J. Histochem. Cytochem. 1984; 32: 894-8.
13. Teixeira C, Tanaka S, Haruma K et al. Carcinoembryonic antigen staging patterns and the invasive tumour margin predict the malignant potential of colorectal carcinoma. Oncology 1994; 51: 228-33.
14. Goslin R, O'Brien M, Steele G et al. Correlation of plasma CEA and CEA tissue staining in poorly differentiated colorectal cancer. Am. J. Med. 1981; 71: 246-53.
15. Denk H, Tappeiner G, Eckerstorfer R et al. Carcinoembryonic antigen in gastrointestinal and extraintestinal tumors and its relationship to tumor cell differentiation. Int. J. Cancer 1972; 10: 262-72.
16. Thompson J, Zimmerman W. The carcinoembryonic antigen gene family: Structure, expression and evolution. Tumor Biol. 1988; 9: 63-83.
17. Benchimoi S, Fuks A, Jothy S et al. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 1989; 57: 327-34.
18. Pignatelli M, Durbin H, Bodmer W. Carcinoembryonic antigen functions as an accessory adhesion molecule mediating colon epithelial cell-collagen interactions. Proc. Natl Acad. Sci. 1990; 87: 1541-5.
19. Jessup J, Thomas P. Carcinoembryonic antigen: Function in metastasis by human colorectal carcinoma. Cancer Metastasis Rev. 1989; 8: 263-80.
20. Wagner H, Toth C, Steele G, Thomas P. Metastatic potential of human colon cancer cells: Relationship to cellular differentiation and carcino-embryonic antigen production. Clin. Exp. Metastasis 1992; 10: 25-31.
21. Hostetter R, Augustus L, Mankarious R et al. Carcinoembryonic antigen as a selective enhancer of colorectal cancer metastasis. J. Natl Cancer Inst., 1990; 82: 380-5.
22. Medoff J, Clack V, Roche J. Characterization of an immunosuppressive factor from malignant ascites that resembles a factor induced in vitro by carcinoembryonic antigen. J. Immunol. 1986; 137: 2057-64.
23. Medoff J, Jegasothy B, Roche J. Carcinoembryonic antigen-induced release of a suppressive factor from normal human lymphocytes in vitro. Cancer Res. 1984; 44: 5822-7.
24. Kammerer R, von Kleist S. CEA expression of colorectal adenocarcinomas is correlated with their resistance against LAK-cell lysis. Int. J. Cancer 1994; 57: 341-7.
25. Herbeth B, Bagrel A. A study of factors influencing plasma CEA levels in an unselected population. Oncodev. Biol. Med. 1980; 1: 191-8.
26. Tabor E, Gerety R, Needy C, Elisberg B, Colon A, Jones R. Carcinoembryonic antigen levels in asymptomatic adolescents. Eur. J. Cancer 1981; 17: 257-8.
27. Fletcher RH. Carcinoembryonic antigen. Annals Intern. Med. 1986; 104: 66-73.
28. Seregni E, Bombardier E, Bogni A, Crippa F, De Jager E, Buraggi G. The role of serum carcinoembryonic antigen (CEA) in the management of patients with colorectal carcinoma. Int. J. Biol. Markers 1992; 7: 167-70.
29. Clarke C, Hine K, Dykes P, Whitehead T, Whitfield A. Carcinoembryonic antigen and smoking. J. R. Coll. Physicians Lond. 1980; 14: 227-8.
30. Thomas P, Hems D. The hepatic clearance of circulating native and asialo carcinoembryonic antigen by the rat. Biochem. Biophys. Res. Commun. 1975; 67: 1205-9.
31. Tabuchi Y, Deguchi H, Imanishi K, Saitoh Y. Comparison of carcinoembryonic antigen levels between portal and peripheral blood in patients with colorectal cancer: Correlation with histopathological variables. Cancer 1987; 59: 1283-8.
32. Ladenson J, McDonald J, Landi M, Schwartz M. Colorectal carcinoma and carcinoembryonic antigen (CEA). Clin. Chem. 1980; 26: 1213-20.
33. Steele G, Ellenberg S, Ramming K et al. CEA monitoring among patients in multi-institutional adjuvant GI therapy protocols. Ann. Surg. 1982; 196: 162-9.
34. Slentz K, Senagor A, Hibbert J, Mazier WP, Talbott TM. Can preoperative and postoperative CEA predict survival after colon cancer resection? Am. Surg. 1994; 60: 528-31.
35. Wang J, Tang R, Chiang J. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis. Colon Rectum 1994; 37: 272-7.
36. Arnaud J, Koehi C, Adeoff M. Carcinoembryonic antigen (CEA) in diagnosis and prognosis of colorectal carcinoma. Dis. Colon Rectum 1980; 23: 141-4.
37. Mach J, Vienny H, Jaeger P et al. Long-term follow-up of colorectal carcinoma patients by repeated CEA radioimmunoassay. Cancer 1978; 42: 1439-47.
38. Yeatman T, Bland K, Copeland E et al. Relationship between colorectal liver metastases and CEA levels in gallbladder bile. Ann. Surg. 1989; 210: 505-12.
39. Paganuzzi M, Onetto M, de Paoli M et al. CEA in serum and bile of colorectal cancer patient with or without detectable liver metastases. AntiCancer Res. 1994; 14: 1409-12.
40. McCall J, Black RB, Rich C et al. The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer. Dis. Colon Rectum 1994; 37: 875-81.
41. Kronborg O, Fenger C, Deichgräber E, Hansen L. Follow-up after radical surgery for colorectal cancer. Design of a randomised study. Scand. J. Gastroenterol. 1988; 49: 159-62.
42. Bruinvels D, Stiggelbout A, Kievit J, van Houwelingen H, Habbema J, van der Velde C. Follow up of patients with colorectal cancer. A meta-analysis. Ann. Surg. 1994; 219: 174-82.
43. Tranberg K, Bengmark S. Metastatic tumours of the liver. In: Blumgart L (ed.). Surgery of the Liver and Biliary Tract. Churchill Livingstone Press, 1994; 1385-97.
44. Scheele J, Stangl R, Altendorf-Hoffman A. Hepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural history. Br. J. Surg. 1990; 77: 1241-6.
45. Allen-Mersh T, Earlam S, Fordy C, Abrams K, Houghton J. Quality of life and survival with continuous hepatic artery floxuridine infusion for colorectal liver metastases. Lancet 1994; 344: 1255-60.
46. Rougier P, Laplanche A, Huguier M et al. Hepatic arterial infusion of Floxuridine in patients with liver metastases from colorectal carcinoma: Long term results of a prospective randomized trial. J. Clin. Oncol. 1992; 10: 1112-18.
47. Martin E, Minton J, Carey L. CEA-directed second-look surgery in the asymptomatic patient after primary resection of colorectal carcinoma. Ann. Surg. 1985; 202: 310-17.
48. Behbehani A, Al-Naqeeb N, Omar Y et al. Serial determination of serum CEA in monitoring management of patients with colorectal carcinoma. Oncology 1990; 47: 303-7.
49. Wanebo H, Llaneras M, Martin T, Kaiser D. Prospective monitoring trial for carcinoma of colon and rectum after surgical resection. Surg. Gynecol. Obstet. 1989; 169: 479-87.
50. Minton J, Hoehn J, Gerber D et al. Results of a 400 patient carcinoembryonic antigen second-look colorectal cancer study. Cancer 1985; 55: 1284-90.
51. Staab H, Anderer F, Stumpf E, Hornung A, Fischer R, Kieninger G. Eighty-four potential second look operations based on sequential carcinoembryonic antigen determinations and clinical investigations in patients with recurrent gastrointestinal cancer. Am. J. Surg. 1985; 149: 198-204.
52. Beart R, Metzger P, O'Connell M, Schutt A. Postoperative screening of patients with carcinoma of the colon. Dis. Colon Rectum 1981; 24: 585-9.
53. Carl J, Bentzen SM, Norgaard-Pedersen B, Kronberg O. Modelling of serial carcinoembryonic antigen changes in colorectal cancer. Scand. J. Clin. Lab. Invest. 1993; 53: 751-5.
54. Allen-Mersh TG. Aspects of treatment. Serum CEA in the follow-up of colorectal carcinoma: Experience in a district general hospital. Ann. R. Coll. Surg. Engl. 1984; 66: 14-16.
55. Wood C, Ratcliffe J, Burt R, Malcolm A, Blumgart L. The clinical significance of the pattern of elevated serum carcinoembryonic antigen (CEA) levels in recurrent colorectal cancer. Br. J. Surg. 1980; 67: 46-8.
56. Umehara Y, Kimura R, Yoshida M, Oba N, Harada Y. Comparison of doubling times of serum carcinoembryonic antigen produced by various metastatic lesions in recurrent gastric and colorectal carcinomas. Cancer 1993; 71: 4055-9.
57. Boey J, Cheung H, Lai C, Wong J. A prospective evaluation of serum carcinoembryonic antigen (CEA) levels in the management of colorectal carcinoma. World J. Surg. 1984; 8: 279-86.
58. Kimura O, Kaibara N, Nishidoi H et al. Carcinoembryonic antigen slope analysis as an early indicator for recurrence of colorectal carcinoma. Jpn. J. Surg. 1986; 16: 106-11.
59. Sugarbaker P, Gianola F, Dwyer A, Neuan N. A simplified plan for follow-up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologic test results. Surgery 1987; 102: 79-87.
60. Rocklin M, Senagore A, Talbott T. Role of carcinoembryonic antigen and liver function tests in the detection of recurrent colorectal carcinoma. Dis. Colon Rectum 1991; 34: 794-7.
61. Sears H, Herlyn M, Engstrom P, Shen J, Atkinson B, Koprowski H. Circulating tumor markers and assessment of response to intrahepatic chemotherapy of colon carcinoma. Am. J. Clin. Oncol. 1985; 8: 108-17.
62. Barone C, Astone A, Cassano A et al. Advanced colon cancer: Staging and prognosis by CEA test. Oncology 1990; 47: 128-32.
63. Carl J, Brunsgaard N, Kjaer M, Norgaard-Pedersen B. Estimated treatment responses in metastatic colorectal carcinoma based on longitudinal carcinoembryonic antigen series. Scand. J. Clin. Lab. Invest. 1993; 53: 829-34.
64. Quentmeier A, Schlag P, Hohenberger P, Schwarz V, Abel U. Assessment of serial carcinoembryonic antigen: Determinations to monitor the therapeutic progress and prognosis of metastatic liver disease treated by regional chemotherapy. J. Surg. Oncol. 1989; 40: 112-18.
65. Smith A, Gordon A, Browning G, Williams A, Sturgeon C. Seth J. Postoperative monitoring of CEA in the prediction of surgical outcome in colorectal cancer. J. R. Coll. Surg. Edinb. 1985; 30: 294-8.
66. Strangl R, Altendorf-Hofman A, Charnley R, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet 1994; 343: 1405-10.
67. Hohenberger P, Schlag P, Gerneth T, Herfath C. Pre- and postoperative carcinoembryonic antigen determinations in hepatic resection for colorectal metastases. Predictive value and implications for adjuvant treatment based on multivariate analysis. Ann. Surg. 1994: 219: 135-43.
68. Preketes A, King J, Caplehorn J, Clingan P, Ross W, Morris D. CEA reduction after cryotherapy for liver metastases from colon cancer predicts survival. Aust. N.Z. J. Surg. 1994; 64: 612-14.
69. Morris D, Ross W. Cryoablation for liver tumours: Metastases: Australian experience. Surg. Oncol. Clin. Nth Am. 1995: (in press).
70. Kievit J, van de Velde C. Utility and cost of carcinoembryonic antigen monitoring in colon cancer follow-up evaluation. A Markov analysis. Cancer 1990; 65: 2580-7.